[go: up one dir, main page]

AU2001293553A1 - Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment - Google Patents

Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment

Info

Publication number
AU2001293553A1
AU2001293553A1 AU2001293553A AU9355301A AU2001293553A1 AU 2001293553 A1 AU2001293553 A1 AU 2001293553A1 AU 2001293553 A AU2001293553 A AU 2001293553A AU 9355301 A AU9355301 A AU 9355301A AU 2001293553 A1 AU2001293553 A1 AU 2001293553A1
Authority
AU
Australia
Prior art keywords
phosphatidylserine
mimicking
apoptosis
bodies
carrying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001293553A
Inventor
Anthony E. Bolton
Arkady Mandel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasogen Ireland Ltd
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Publication of AU2001293553A1 publication Critical patent/AU2001293553A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001293553A 2000-09-18 2001-09-18 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment Abandoned AU2001293553A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002319928A CA2319928A1 (en) 2000-09-18 2000-09-18 Apoptosis-mimicking synthetic entities and use thereof in medical treatments
CA2319928 2000-09-18
PCT/CA2001/001328 WO2002024162A1 (en) 2000-09-18 2001-09-18 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment

Publications (1)

Publication Number Publication Date
AU2001293553A1 true AU2001293553A1 (en) 2002-04-02

Family

ID=4167153

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001293553A Abandoned AU2001293553A1 (en) 2000-09-18 2001-09-18 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment

Country Status (6)

Country Link
US (1) US6953591B2 (en)
EP (1) EP1324750A1 (en)
JP (1) JP2004508423A (en)
AU (1) AU2001293553A1 (en)
CA (2) CA2319928A1 (en)
WO (1) WO2002024162A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI281407B (en) * 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
EP1427394B1 (en) * 2001-09-18 2007-03-14 Vasogen Ireland Limited Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities
CA2458720A1 (en) * 2001-09-18 2003-03-27 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatment
GB0207653D0 (en) * 2002-04-03 2002-05-15 Lamellar Therapeutics Ltd Methods of using lamellar bodies for therapeutic purposes
WO2005007240A1 (en) * 2003-07-21 2005-01-27 Vasogen Ireland Limited Combination treatment of neurological disorders comprising phospholipids
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
JP4891522B2 (en) * 2003-10-03 2012-03-07 株式会社ファンケル Serum GOT, GPT improving agent
JP2007522259A (en) * 2004-10-20 2007-08-09 ドゥサン コーポレーション A composition containing phosphatidylserine for skin maintenance / improvement or skin barrier function enhancement
GB0426481D0 (en) 2004-12-02 2005-01-05 Vaccine Technology Ltd Composition
WO2006107107A1 (en) * 2005-04-01 2006-10-12 Fumitaka Ohsuzu Myocardial protective agent comprising phospholipid liposome and method for prevention of myocardial disorder occurring under ischemia/reperfusion
WO2007041279A2 (en) * 2005-09-29 2007-04-12 S-Cell Biosciences, Inc. Methods to treat t-cell disorders using tisf
ITRM20070394A1 (en) * 2007-07-16 2009-01-17 Uni Cattolica Del Sacro Cuo Re ASYMMETRIC LIPOSOMAS AND THEIR USE IN MEDICAL FIELD.
CN102046151A (en) * 2008-03-26 2011-05-04 牛津大学 Endoplasmic reticulum targeting liposomes
EP2410989A2 (en) 2009-03-27 2012-02-01 The Chancellor, Masters and Scholars of the University of Oxford Cholesterol level lowering liposomes
WO2011098407A1 (en) * 2010-02-12 2011-08-18 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Microspheres
EP2630493A4 (en) * 2010-10-22 2014-05-21 Univ Florida MICROPARTICLES TARGETING SPECIFIC ANTIGENS THAT INDUCE TOLERANCE AND USES THEREOF
CN117205331A (en) 2011-04-29 2023-12-12 西莱克塔生物科技公司 Tolerogenic synthetic nanocarriers for reducing antibody responses
WO2013019658A2 (en) 2011-07-29 2013-02-07 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
EP3184121A3 (en) * 2012-07-25 2017-09-27 Salk Institute For Biological Studies Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases
CN110639024A (en) 2013-05-03 2020-01-03 西莱克塔生物科技公司 Methods and compositions for enhancing CD4+ regulatory T cells
CN112933234A (en) 2013-06-04 2021-06-11 西莱克塔生物科技公司 Repeated administration of non-immunosuppressive antigen-specific immunotherapeutics
JP6546195B2 (en) * 2014-01-17 2019-07-17 フンダシオ・インスティトゥート・ディンベスティガシオ・エン・シエンシス・デ・ラ・サルー・ヘルマンス・トリアス・イ・プホル Liposome-based immunotherapy
AU2015279738A1 (en) 2014-06-25 2016-12-22 Selecta Biosciences, Inc. Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors
BR112017001601A2 (en) 2014-09-07 2017-11-21 Selecta Biosciences Inc methods and compositions for attenuating immune responses of the modulating antiviral transfer vector of gene expression
GB201511058D0 (en) * 2015-06-23 2015-08-05 Lamellar Biomedical Ltd Compositions and methods for using lamellar bodies for therapeutic purposes
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
JP7262100B2 (en) 2016-04-29 2023-04-21 アイカーン スクール オブ メディスン アット マウント サイナイ Targeting the innate immune system to induce long-term tolerance and resolve macrophage accumulation in atherosclerosis
JP2019533718A (en) 2016-09-27 2019-11-21 セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. Recombinant immunotoxin for use in the treatment of cancer
CN110325203A (en) 2017-01-07 2019-10-11 西莱克塔生物科技公司 Medelling with the immunosuppressor of synthesis nano-carrier coupling is administered
MX2019010757A (en) 2017-03-11 2020-01-20 Selecta Biosciences Inc METHODS AND COMPOSITIONS RELATED TO THE COMBINED TREATMENT WITH ANTI-INFLAMMATORY AND SYNTHETIC NANPORTERS THAT INCLUDE AN IMMUNOSUPPRESSOR.
BR112020007157A2 (en) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. methods and compositions for the attenuation of viral transfer anti-vector igm responses
WO2019183637A1 (en) 2018-03-23 2019-09-26 University Of Washington Immunosuppressive materials and related methods
WO2020018583A1 (en) 2018-07-16 2020-01-23 Selecta Biosciences, Inc. Methods and compositions of otc constructs and vectors
KR20210034015A (en) 2018-07-16 2021-03-29 셀렉타 바이오사이언시즈, 인크. Methods and compositions of MMA constructs and vectors
CA3138525A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
KR20220015425A (en) 2019-05-28 2022-02-08 셀렉타 바이오사이언시즈, 인크. Methods and compositions for attenuated antiviral transfer vector immune response
IL302539A (en) 2020-11-04 2023-07-01 Selecta Biosciences Inc Compositions for reducing immune responses against immunoglobulin proteases
EP4274571A1 (en) 2021-01-05 2023-11-15 Selecta Biosciences, Inc. Viral vector dosing protocols
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
US20220323607A1 (en) 2021-04-09 2022-10-13 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023064350A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Viral vector dosing protocols
WO2023064887A1 (en) 2021-10-15 2023-04-20 The Board Of Trustees Of The University Of Illinois Mechanochemical dynamic therapy for focal cancer treatment
WO2023086615A1 (en) 2021-11-14 2023-05-19 Selecta Biosciences, Inc. Multiple dosing with viral vectors
WO2023133319A1 (en) 2022-01-10 2023-07-13 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and synthetic nanocarrier dose sparing
US20230322884A1 (en) 2022-03-09 2023-10-12 Selecta Biosciences, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists and related dosing
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
US20230372535A1 (en) 2022-03-25 2023-11-23 Selecta Biosciences, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists and anti-igm agents
US20230381277A1 (en) 2022-04-08 2023-11-30 Selecta Biosciences, Inc. High affinity il-2 receptor agonists and immunosuppressants to enhance immune tolerance
KR102796922B1 (en) * 2022-04-11 2025-04-15 연세대학교 원주산학협력단 Cationic lipid nanoparticles for mRNA vaccine
CN120813689A (en) 2022-08-11 2025-10-17 笛卡尔疗法股份有限公司 Compositions and methods relating to immunoglobulin proteases and fusions thereof
WO2024229370A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Compositions and methods for treating gvhd
WO2024229350A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists for diabetes
WO2024229380A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Immunosuppressant in combination with high affinity il-2 receptor agonists in autoimmune liver diseases
WO2024229432A1 (en) 2023-05-03 2024-11-07 Cartesian Therapeutics, Inc. Synthetic nanocarriers comprising an immunosuppressant in combination with high affinity il-2 receptor agonists to enhance immune tolerance

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1212900B (en) * 1983-11-17 1989-11-30 Valle Francesco Della THERAPEUTIC USE OF PHOSPHATIDYLSERINE IN DISEASES OF THE CENTRAL NERVOUS SYSTEM WITHOUT EFFECTS ON BLOOD COAGULATION
IL84252A (en) * 1987-10-23 1994-02-27 Yissum Res Dev Co Phospholipase inhibiting compositions
US5231090A (en) * 1990-07-30 1993-07-27 University Of Miami Treatment for hypercholesterolemia
IT1247165B (en) 1991-03-15 1994-12-12 Fidia Spa THERAPEUTIC USE OF PHOSPHATIDYLSERINE AND DERIVATIVES IN DEGENERATIVE PATHOLOGIES, ALSO ASSOCIATED WITH IMMUNITARY DYSFUNCTIONS.
DE4117629A1 (en) * 1991-05-29 1992-12-03 Max Planck Gesellschaft Use of phosphatidyl serine derivs. - for treatment of depression and loss of cerebral function e.g. Parkinson's disease and Alzheimer's disease
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
JP3714683B2 (en) 1992-07-30 2005-11-09 生化学工業株式会社 Anti-rheumatic agent
US6312719B1 (en) 1994-03-04 2001-11-06 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
WO1995023592A1 (en) 1994-03-04 1995-09-08 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
US5948756A (en) 1995-08-31 1999-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Therapeutic lipoprotein compositions
US6290987B1 (en) * 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
EP1248628A4 (en) * 1999-12-14 2004-08-04 Sky High Llc Phospholipid compositions as anti-inflammation agents
DK1261785T3 (en) 2000-03-07 2003-10-27 E F P Floor Prod Fussboeden Panel, especially floor panel
AU2001240076A1 (en) 2000-03-08 2001-09-17 National Jewish Medical And Research Center Phosphatidyl serine receptors and uses thereof

Also Published As

Publication number Publication date
US20020086049A1 (en) 2002-07-04
EP1324750A1 (en) 2003-07-09
JP2004508423A (en) 2004-03-18
US6953591B2 (en) 2005-10-11
CA2422686A1 (en) 2002-03-28
WO2002024162A1 (en) 2002-03-28
CA2319928A1 (en) 2002-03-18

Similar Documents

Publication Publication Date Title
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
AU775126C (en) Substituted oxazolidinones and their use in the field of blood coagulation
HUP0203367A3 (en) Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes
AU2001256184A1 (en) 6-aminoalkyl-dihydropyrimidines and the use thereof as medicaments against viraldiseases
AU2001275177A1 (en) Cardiac disease treatment and device
AU2001253565A1 (en) Cardiac disease treatment and device
AU2001275176A1 (en) Cardiac disease treatment and device
AU2001281369A1 (en) Cardiac disease treatment and device
AU2003243551A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
GB0109414D0 (en) Well treatment fluids and methods for the use thereof
AU2002227300A1 (en) Reducing cellular damage in the human body
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
AU4289100A (en) Dihydropyrimidines and their use in the treatment of hepatitis
HUP0400069A3 (en) Pharmaceutical combinations and their use in preventing and treating the thrombosis
AU1164601A (en) Therapeutic use and formulation
WO2003099841A9 (en) Peptides and the use thereof in darkening the skin
AU5240700A (en) Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
AU2837301A (en) Use of polymeric material in the treatment of hard surfaces
AU2002243363A1 (en) Use of aziridino-compounds in the treatment of immune dysfunctions
AU2003238242A1 (en) Use of an anti-endotoxin drug in the prevention and treatment of disease
AU2001292797A1 (en) Metal complexes for use in medical and therapeutic applications
AU2001261375A1 (en) Human caspase-12 materials and methods
GB0011052D0 (en) Medical device and use thereof
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
AU6091299A (en) Treatment device, treatment bed to be used therein and the use thereof